2025年10月27日，金城医药(300233.SZ)发布2025年第三季报。截至2025年10月26日，共有9个机构投资 者披露持有金城医药A股股份，合计持股量达1.13亿股，占金城医药总股本的29.44%。其中，机构投资 者包括淄博金城实业投资股份有限公司、全国社保基金五零二组合、中国建设银行股份有限公司-富国 精准医疗灵活配置混合型证券投资基金、青岛富和投资有限公司、基本养老保险基金二一零八组合、全 国社保基金六零一组合、香港中央结算有限公司、招商银行股份有限公司-兴全轻资产投资混合型证券 投资基金(LOF)、国泰佳泰股票专项型养老金产品-招商银行股份有限公司，机构投资者合计持股比例达 29.44%。相较于上一季度，机构持股比例合计上涨了4.77个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计2个，包括富国精准医疗灵活配置混合A、兴全 轻资产混合(LOF)。本期较上一季未再披露的公募基金共计14个，主要包括大成景恒混合A、大成卓享 一年持有混合A、太平嘉和三个月定开债券发起式、平安添悦债券A、国泰融安多策略灵活配置混合A 等。 对于社保基金，本期新披露持有金城医药的社保基金共计2个，包括全国 ...

公募基金方面，本期较上一期持股增加的公募基金共计4个，包括汇添富创新医药混合A、广发医疗保 健股票A、富国精准医疗灵活配置混合A、汇添富医疗服务灵活配置混合A，持股增加占比达1.45%。本 期较上一季度持股减少的公募基金共计1个，即中欧医疗健康混合A，持股减少占比达1.66%。本期较上 一季度新披露的公募基金共计1个，即长城医药产业精选混合发起式A。本期较上一季未再披露的公募 基金共计114个，主要包括广发科技创新混合A、中欧医疗创新股票A、工银前沿医疗股票A、兴全合润 混合A、广发医药健康混合A等。 2025年10月25日，昂利康(002940.SZ)发布2025年第三季报。截至2025年10月24日，共有9个机构投资者 披露持有昂利康A股股份，合计持股量达9435.69万股，占昂利康总股本的46.77%。其中，机构投资者 包括嵊州市君泰投资有限公司、浙江昂利康制药股份有限公司-第一期员工持股计划、浙江昂利康制药 股份有限公司-第一期员工持股计划、中国银行股份有限公司-广发医疗保健股票型证券投资基金、中国 工商银行股份有限公司-中欧医疗健康混合型证券投资基金、中国建设银行股份有限公司-富国精准医疗 灵活配置 ...

Group 1 - In April 2025, out of 8,451 comparable mixed funds, 1,899 funds saw an increase in net value, while 6,529 funds experienced a decline, and 23 funds remained flat [1] - The top two performing funds for April were Zhonghang Youxuan Lihang Mixed Fund A and C, with returns of 17.30% and 17.25% respectively [1] - These two funds, established on December 24, 2024, have cumulative returns of 42.99% and 42.67% as of April 30, 2025 [1] Group 2 - Nine funds under Huatai Fuhua Fund Management Co., Ltd. achieved monthly returns exceeding 10%, including Huatai Fuhua North Exchange Innovation Selected Mixed Fund A and C [2] - The Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A had a return of 12.18% in April and a cumulative return of 55.60% since its inception [3] - The fund manager believes the pharmaceutical industry will show strong anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier medical equipment [3] Group 3 - The top-performing funds in April included Huatai Fuhua Medical Service Flexible Allocation Mixed Fund A, with a scale of 4.408 billion yuan, and a cumulative net value of 1.5560 yuan [3] - The two funds, Fuguo Precision Medical Flexible Allocation Mixed Fund A and Zhongyin Innovation Medical Mixed Fund A, also performed well with returns of 11.21% and 10.57% respectively [4][5] - Fuguo Precision Medical Flexible Allocation Mixed Fund A has a cumulative return of 184.98% since its inception [4] Group 4 - A total of 59 mixed funds saw declines exceeding 10% in April, with Tianzhi Quantitative Core Selected Mixed Fund C and A at the bottom with returns of -18.19% and -18.18% respectively [5] - These funds have cumulative returns of -45.73% and -46.21% since their inception [5] - The top ten holdings of these underperforming funds included companies in the optical and semiconductor sectors [5][6]